Introduction
On 1 February 2016, the World Health Organization (WHO) declared that the recent cluster of microcephaly cases and other neurological disorders reported in the Americas, where an outbreak of Zika virus infection is ongoing, constitutes a public health emergency of international concern. 1 Zika virus is a mosquito-borne virus related to yellow fever, dengue, West Nile, Japanese encephalitis and tick-borne encephalitis viruses which all belong to the virus family Flaviviridae and genus Flavivirus. Flaviviruses are positivesense ribonucleic acid (RNA) viruses, with a genome of approximately 11 kilobases. Virions are produced as spherical particles, 40-60 nm in diameter. 2 The virus was first isolated in 1947 from rhesus monkeys living in the Zika forest in Uganda. 3 Up to 2006, only sporadic cases of humans infected with the virus had been reported in the literature. 4 Accordingly, Zika virus was long considered a low-impact human pathogen, until outbreaks were reported in Yap Island in the Federated States of Micronesia in 2007 with 118 confirmed and suspected cases 5 and in French Polynesia in 2013-2014 with an estimated 30 000 cases. 6 This might explain the limited number of articles listed in the PubMed database up to 21 January 2016 (269) compared with that for other mosquito-borne viruses such as dengue virus (9187), West Nile virus (5949) and chikungunya virus (2183). 3, 4 Zika virus infection is often asymptomatic; around 80% of patients showed few or no clinical symptoms during the outbreaks in Yap Island and French Polynesia. 5, 6 The incubation period for the infection was estimated to range from 3 to 12 days. [6] [7] [8] Common symptoms in confirmed patients are a maculopapular rash (90-96% of cases), fever (62-65%), myalgia and arthralgia (48-65%), headache (45-58%), nonpurulent conjunctivitis (38-55%) and retro-orbital pain (40%). [6] [7] [8] Interim case definitions were published by WHO on 12 February 2016. 9 A major concern is the possible association of Zika virus infection with Guillain-Barré syndrome -a neurological disorder -and with microcephaly and other neurological manifestations in newborns of infected mothers. These complications have been noticed in the current epidemic region and were identified retrospectively in the French Polynesia outbreak. 8, 10 However, the question arises whether the increased incidences of Guillain-Barré syndrome and microcephaly in the current outbreak are due to certain specific virulent strains or to a common pattern of all Zika virus strains that have gone unnoticed because of the low number of cases in previous outbreaks. 8 In Brazil, more than 4700 cases of suspected microcephaly were recorded from mid-2015 to the end of January 2016, whereas the number usually is below 200 cases per year. 11 Brazil, the Bolivarian Republic of Venezuela, Colombia, El Salvador and Suriname reported spikes in Guillain-Barré syndrome cases in January 2016. 12, 13 While it remains to be determined if Zika virus infection causes these complications, several governments and health agencies have issued precautionary travel advice Objective To review the state of knowledge about diagnostic testing for Zika virus infection and identify areas of research needed to address the current gaps in knowledge. Methods We made a non-systematic review of the published literature about Zika virus and supplemented this with information from commercial diagnostic test kits and personal communications with researchers in European preparedness networks. The review covered current knowledge about the geographical spread, pathogen characteristics, life cycle and infection kinetics of the virus. The available molecular and serological tests and biosafety issues are described and discussed in the context of the current outbreak strain. Findings We identified the following areas of research to address current knowledge gaps: (i) an urgent assessment of the laboratory capacity and capability of countries to detect Zika virus; (ii) rapid and extensive field validation of the available molecular and serological tests in areas with and without Zika virus transmission, with a focus on pregnant women; (iii) monitoring the genomic diversity of circulating Zika virus strains; (iv) prospective studies into the virus infection kinetics, focusing on diagnostic sampling (specimen types, combinations and timings); and (v) developing external quality assessments for molecular and serological testing, including differential diagnosis for similar viruses and symptom clusters. The availability of reagents for diagnostic development (virus strains and antigens, quantified viral ribonucleic acid) needs to be facilitated. Conclusion An international laboratory response is needed, including preparation of protocols for prospective studies to address the most pressing information needs.
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for the affected regions, with specific information for pregnant women. 14 The Zika virus outbreak is also likely to increase the number of cases exported from epidemic areas by travellers ( Table 1) . The current epidemic has therefore resulted in a large increase in requests for laboratory diagnosis of suspected cases of Zika virus infection not only among residents of the outbreak region but also among travellers returning from affected areas, especially pregnant women with or without current or past clinical symptoms of a Zika virus infection. We therefore identified a need to assess the current state of preparedness in laboratory diagnostics to ensure a timely and accurate response to the Zika virus outbreak in both affected and unaffected regions.
Methods
We made a non-systematic review to present the essential background information and current gaps in knowledge about diagnostic testing for Zika virus infection in humans. We made a literature search of the PubMed database up to 21 January 2016, using the search terms "Zika virus", "ZIKV" or "Zika", with no date or language restriction. This was supplemented by information obtained from commercially available diagnostic test kits and from personal communications with researchers in European preparedness networks. We identified areas of research and actions needed to address the identified gaps in international laboratory preparedness for an adequate response to the current outbreak.
Epidemiology Geographical spread
Serological, epidemiological and entomological studies have reported the circulation of the virus in tropical areas of western Africa, central Africa and in Asia.
3 By 14 April 2016, Zika virus autochthonous transmission had been reported in 35 countries in the Americas. 27 The increased risk of importing Zika virus to Europe is illustrated by recent reports of cases of the virus in travellers to many European countries.
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Pathogen and transmission pathways
Zika virus belongs to the Spondweni virus serogroup of mosquito-borne flaviviruses (Fig. 1) . Phylogenetic analysis reveals the existence of two lineages (Fig. 2) : the African lineage, which has shown no propensity to disseminate outside of Africa, and the Asian lineage, which continues to seed in previously unaffected regions of the world. 3 All recently disseminated strains belong to the Asian lineage. 29 31, 32 In addition, genomic RNA was detected in Senegal in mosquitoes of three species: Mansonia uniformis, Culex perfuscus and Anopheles coustani. Ae. albopictus has shown competence in Zika virus dissemination in laboratory studies but has never been implicated in Zika virus epidemiology in the field outside of Africa. 32, 33 Additional modes of transmission have been identified. Perinatal transmission most probably occurs by transplacental transmission or during delivery by an infected mother. 34 Sexual transmission has been indicated in multiple cases. 35 Zika virus has been isolated from semen collected 14 days after the start of symptoms, 36 while detection of the Zika virus genome was described in semen at 28 and 62 days after the onset of symptoms. 37 The potential for Zika virus transmission via blood transfusion was identified in the French Polynesia outbreak in [2013] [2014] 38 and the Bra- 
Infection kinetics
Knowledge of the Zika virus infection kinetics is essential to determine the optimal strategy for diagnosis. This is hindered by the fact that only a few diagnosed cases of human Zika virus infection, all of Asian lineage, are described in the literature. Zika virus has been detected in serum, saliva, urine and nasopharyngeal swabs by molecular methods. In serum, the virus can be detected typically up to 3-5 days after the onset of clinical symptoms; the viral load seems to peak when clinical signs appear. 41, 43 The time frame of detection in saliva is no longer than in serum. A study combining the diagnostic results from blood and saliva specimens from 182 suspected cases increased the rate of detection; 19% of the total of 103 positive cases were detected in saliva only while 52 cases were detected with both saliva and serum. 40 Data from observations of six patients in the French territory of New Caledonia and from other case reports suggested that detection of Zika virus in urine should be supplemented by molecular testing of blood samples. 18, 23, 41 The viral load in urine was higher than in blood, peaking at days 5-7, and seemed to last longer, with detection by PCR assay possible up to 20 days after clinical onset of Zika virus disease. 41 In one case, Zika virus RNA was still detected in patient's urine at day 28 after the onset of illness (authors' own unpublished observations, Erasmus University Medical Centre, January 2016). Virus isolation from urine from a case using Vero cells has been described. 17 Detection of Zika virus RNA in nasopharyngeal swabs when serum samples were negative was described in two cases. 17, 44 The low invasiveness of urine and saliva collection is an advantage for diagnosis of infants and newborns. More studies on detection of Zika virus in different types of specimens are needed, as these observations are based on a limited number of cases.
Immune response
Typically for flaviviruses, immunoglobulin (Ig) M antibodies develop within a few days after onset of illness and can generally be detected for up to 3 months. IgG antibodies develop within days after IgM and can be detected for months to years. Cases have been described with persistence of IgM antibodies for longer periods, which complicates accurate diagnostic testing. 45 Immune response from Zika virus infection has only been described in 11 patients during the Zika virus outbreak on Yap Island. IgM was detected as soon as 3 days after the onset of symptoms. IgG appeared after day 10 in a patient with no history of previous flavivirus infections. 43, 46, 47 In this patient, neutralizing antibodies against Zika virus could be detected as early as 5 days after the onset of fever.
Specific attention should be given in prospective studies to determine the Zika virus immune responses in pregnant women, since antibody responses during pregnancy may be different from those in non-pregnant women.
48
Laboratory diagnosis
To run molecular tests in an outbreak setting, laboratories need knowledge and experience of quality control and validation, access to rapid supply chains for reagents and plastics, and the capability to increase the throughput of testing. To speed up testing, experience with automated equipment for nucleic acid extraction and RT-PCR assay are essential.
In serological assays, extensive cross-reactivity between virus genus members or geographical overlap with other pathogens causing overlapping syndromes might occur. In these cases, pan-genus and syndromic serum panel tests and antigens need to be available and confirmatory techniques such as enzyme-linked immunosorbent assay (ELISA), immunofluorescence assay and virus neutralizing testing are required.
Molecular methods
Molecular diagnosis of Zika virus can be done on different types of body fluids: whole blood, serum, EDTA (ethylenediaminetetraacetic acid) plasma, saliva and urine. Urine and saliva should be considered together with blood and/ or serum in the algorithm of Zika virus genome detection using molecular techniques. The reliance on the use of molecular diagnostics to rule out infection requires careful consideration, as the experience of clinicians and diagnostic laboratories is necessarily limited for emerging diseases. Several noncommercial RT-PCR tests for Zika virus have been described in the literature, but few provide validation using the most 
RT-PCR
Zika-virus-specific
Various real-time and conventional RT-PCR assays specific for Zika virus have been described (Table 2) . 19, 43, 51, 52 Lanciotti at al. 43 described a combination of two real-time PCR assays and this approach is the most commonly used for direct diagnosis of Zika virus. Two gene targets were described and equivocal positive results were mentioned that could be related to false positives; of 157 samples tested, 10 were positive for only one target while 17 were positive for both. 43 It was not mentioned whether this was randomly observed with both assays. However, discrepant results were observed between the two targets in the French and Dutch reference laboratories as well (authors' own unpublished observations). Primer/probe set 1 in combination with TaqMan® Fast Virus 1-Master Mix (Life Technologies, Bleiswijk, Netherlands) was found to be less sensitive than set 2 (decrease of about 3 cycle thresholds) and showed worse amplification plots with Zika viruses of African lineage. For set 2, African and Asian lineages of the virus had comparable sensitivity and amplification plots. Sequencing of PCR products demonstrated that positivity with only set 1 was shown to be due to false positives rather than a lack of sensitivity of set 2. Recently, this assay was used to detect Zika virus RNA in the amniotic fluid of two pregnant women, from the state of Paraiba, Brazil, whose fetuses were diagnosed with fetal microcephaly.
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Other researchers have described an assay using a locked nucleic acid probe in a real-time RT-PCR assay for detection of Zika virus in human serum (Table 2) , 52 although the probe should be FAM-CTYAGACCAGCTGAAG-BBQ, with the locked nucleic acids indicated in bold type (M Weidmann, University of Stirling, personal communication, January 2016). Although no studies have yet been published, several laboratories are currently identifying Zika virus infection in humans using this assay (B Rockx, Dutch National Institute for Public Health and the environment, personal communication, February 2016). In general, locked nucleic acid and minor groove binder probes are not the best choice in PCR screening assays, since only one mutation can result in false-negative results due to failure to detect the amplified product. In cases such as Zika virus, where very few sequence data are available and the grade of genome conservation is not known, it is generally recommended to use TaqMan® probes in quantitative RT-PCR.
Commercial RT-PCR assays for Zika virus are rapidly becoming available. However, until now the tests are for research purposes only. The primers and probe sequences in commercial kits are not usually publicly available, which precludes in silico assessment of their fit with the current Zika virus. Commercial kits on the market include: RealStar® . Manufacturers should be encouraged to put detailed information about their primers and probes into the public domain, so that the performance of these can be evaluated continuously in the context of our evolving knowledge about the genomic diversity of Zika virus during the current outbreak.
Pan-flavivirus combined with sequencing
One real-time 56 and several conventional 58,60-62 pan-flavivirus (detecting all viruses of genus Flavivirus) RT-PCR assays have been used in combination with sequencing to detect human Zika virus cases (Table 2) . 15, 17, 18, 57, 59, 64 
Serological methods
The serology of flaviviruses is complex due to extensive cross-reactivity between antibodies triggered by different flavivirus infections or by vaccination, even for viruses belonging to different serogroups. In addition, an acute flavivirus infection might boost cross-reactive antibodies due to previous infection with or vaccination against another flavivirus.
45 Table 3 summarizes by continent which flaviviruses, other than Zika virus, may cause cross-reactivity in serological tests, due to endemic circulation or vaccination. This shows that patients in the current Zika virus outbreak areas are likely to have a high background exposure to other flaviviruses, such as dengue virus, yellow fever virus and West Nile virus, whereas European travellers returning from the same areas may not. As a consequence, a high proportion of the Zika virus infections in the outbreak region will be secondary flavivirus infections that will complicate the serology.
A limited number of Zika virus serological tests have been described in the literature. Data from studies of Zika virus seroprevalence and diagnosis published from 1950 to 1980 show that complement fixation and haemagglutination inhibition tests show extensive cross-reaction between Zika and other flaviviruses. 65, 66 Despite some risk of cross-reactivity, the most specific serological method for flaviviruses are virus neutralization tests. 45 More recent studies, described below, are of Zika virus serological tests developed noncommercially and based on ELISA using whole viral antigen or recombinant protein or on immunofluorescence assay. As these tests have had only limited validation, the laboratory community urgently needs better validation data for serology testing in the field.
Non-commercial tests
Antibody-capture ELISAs for IgM and IgG (with whole inactivated viral antigen produced on suckling mouse brains) were used to map antibody responses in 11 patients from the Yap Island outbreak. 43 A similar technique using whole viral antigen produced in Vero cells, was used to describe the antibody response 10, 22, 43 In a patient with a primary flavivirus infection with Zika virus, comparative neutralization tests only showed neutralizing antibodies against Zika virus and not against the four dengue fever viruses. The interpretation of neutralization tests when a patient has already been infected by or vaccinated against another flavivirus is more complex. Even if the neutralization titre were higher for Zika virus than for other flaviviruses, only a few patients had a titre for Zika virus that was fourfold higher than for other heterologous flaviviruses.
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Commercial tests
To the authors' knowledge three commercial tests are on the market at the time of writing this article or will be available soon. The Zika virus IgG and IgM detection kits of MyBioSource Inc. (San Diego, USA) use a double-antigen sandwich ELISA. No information on the type of antigens used or on the test specificity and sensitivity is given by the manufacturer. 67 Biocan Diagnostics Inc. (Coquitlam, Canada) offers a rapid finger-prick assay based on a mix of the NS1 protein and envelope protein that can detect IgM and IgG antibodies. The company states a specificity of 99% but no specific details of the validation procedure are given. 68 Euroimmun AG (Lübeck, Germany) offers both immunofluorescence assay and ELISA for IgM and IgG. The Euroimmun immunofluorescence assay is offered in a mosaic slide together with detection for Zika virus, chikungunya virus and four dengue virus serotypes. The information provided indicates cross-reactivity with antibodies directed against tick-borne encephalitis virus, West Nile virus and dengue viruses for both the IgG and IgM assays. Furthermore, validation data for the IgM and IgG Zika virus immunofluorescence assay indicate a wide range of specificities and sensitivities depending on the validation cohort. The given values are hard to interpret as the description of the cohorts is insufficient. The validation data should be interpreted with caution, as positivity was only rated at the cutoff dilution. This could mean that the specificity may be different (higher) than stated, as the results were not scored as end-titres. The use of end-titres would provide a window for differentiating the (cross) reactivity measured. The ELISA is based on recombinant NS1 protein which leads to a reduction of crossreactivity with other flaviviral antibodies to maximal values of 18.8% (IgG) and 8.3% (IgM). Euroimmun is currently the only manufacturer providing detailed validation data that clearly address the above-mentioned difficulties with crossreactivity in flavivirus serodiagnostics.
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Biosafety
Zika virus is classified as a biosafety level 2 pathogen in the European Union (with the exception of the United Kingdom) and the USA. There are no inactivation data available that are specific for Zika virus. However, flaviviruses are typically inactivated by temperatures above 56 °C for at least 30 minutes, in solutions of pH ≤ 6, by ultraviolet light and by gamma-radiation and are known to be susceptible to disinfectants such as 1% sodium hypochlorite, 2% glutaraldehyde, 70% ethanol, 3-6% hydrogen peroxide and 3-8% formaldehyde.
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During the initial steps of molecular detection methods phenol guanidine isothiocyanate or chaotropic salts are added to the samples to extract the RNA. These reagents inactivate flaviviruses, and therefore the diagnostic procedure could continue in a laboratory with standard safety levels after the addition of these reagents. 75 Although Zika virus is only a level 2 pathogen, laboratories should assess the additional risks for laboratory personnel who are pregnant, especially when the virus is cultured (e.g. in virus neutralization tests).
Synthesis and conclusions
Box 1 summarizes areas for research and action that would address some of Box 1. Areas for research and actions needed to address gaps in knowledge about Zika virus diagnostic testing
• The following areas of research are suggested to address the knowledge gaps identified: -Urgent assessment of the laboratory capacity and capability of countries to detect Zika virus.
-Conducting rapid and extensive field validation of the available molecular and serological tests in areas with Zika virus transmission and in areas unaffected by transmission but receiving returning travellers. Special focus should be on pregnant women.
-Monitoring the genomic diversity of circulating Zika virus strains to allow verification against operational molecular tests to ensure continuous sensitivity of testing.
-Conducting prospective studies into the Zika virus infection kinetics in the general population and in pregnant women. This should focus on determining the ideal types of diagnostic samples (e.g. whole blood, plasma, serum, urine, saliva, etc.), combinations and times of collection (stage of illness).
-Developing external quality assessments for both molecular and serological testing. Besides Zika-virus-positive samples, these panels should include: (i) a cross-reactive panel, consisting of viruses or antibodies to closely related viruses (dengue virus, yellow fever virus, West Nile virus) and (ii) a syndromic panel with pathogens or antibodies to diseases with a clinical manifestation similar to Zika virus (e.g. chikungunya virus, malaria, rickettsia). External quality assessments for molecular testing should address different types of diagnostic samples.
• The availability of reagents for diagnostic development (e.g. virus strains, virus antigens, quantified viral ribonucleic acid) needs to be facilitated. This could be achieved through initiatives such as the European Virus Archive 76 and the future EVD-LabNet by the European Centre for Disease Prevention and Control.
• An international laboratory response is needed, which would include preparation of protocols for prospective studies to address the most pressing information needs. 
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Резюме Обзор накопленного опыта, применимого при разработке новых тестов для диагностики заражения вирусом Зика
Цель Проанализировать изученность тестирования для диагностики заражения вирусом Зика и определить, в какие области исследования необходимо направить деятельность, чтобы восполнить имеющиеся пробелы в знаниях. Методы Авторы провели несистематический обзор опубликованной литературы, посвященной вирусу Зика, и объединили эту информацию с информацией, полученной с помощью коммерческих диагностических тест-наборов и в ходе личного общения с исследователями в европейских системах готовности. В обзор были включены существующие знания о географическом распространении, особенностях возбудителя, жизненном цикле и кинетике вируса. Доступные молекулярные и серологические методы тестирования, а также проблемы в области биобезопасности описаны и изучены в контексте циркулирующего сегодня эпидемического штамма. Результаты Было определено, что в настоящий момент пробелы в знаниях имеются в следующих областях исследования: (i) неотложная оценка лабораторного потенциала и способности стран выявлять вирус Зика; (ii) быстрое и исчерпывающее подтверждение результатов доступных молекулярных и серологических тестов в полевых условиях как в регионах распространения вируса Зика, так и во всех остальных с выделением беременных женщин в группу особого внимания; (iii) отслеживание геномного разнообразия циркулирующих штаммов вируса Зика; (iv) проспективные исследования кинетики вируса, акцентирующие внимание на взятии проб для диагностики (виды, сочетания проб и сроки их взятия); (v) разработка процедур внешней оценки качества молекулярных и серологических методов тестирования, в том числе дифференциальной диагностики для схожих вирусов и симптомокомплексов. Необходимо увеличить доступность реагентов для развития диагностики (штаммы и антигены вируса, вирусная рибонуклеиновая кислота в количественном выражении). Вывод От лабораторий всего мира требуются ответные действия, включающие подготовку инструкций для проспективных исследований, которые позволили бы удовлетворить наиболее неотложные потребности в информации.
Resumen
Revisión de antecedentes para el desarrollo de pruebas de diagnóstico para la infección por el virus de Zika
Objetivo Revisar el estado del conocimiento sobre las pruebas de diagnóstico para la infección por el virus de Zika e identificar las áreas de investigación necesarias para abordar las actuales lagunas en los conocimientos. Métodos Se llevó a cabo una revisión no sistemática de las publicaciones sobre el virus de Zika y se complementó con información derivada de equipos de pruebas de diagnóstico comerciales y comunicaciones personales con investigadores de redes de preparación europeas. La revisión abarcó el conocimiento actual sobre la propagación geográfica, las características patógenas, el ciclo de vida y la cinética de infección del virus. Las pruebas moleculares y serológicas disponibles, así como temas relativos a la bioseguridad, se describen y debaten en el contexto de la cepa del brote actual. 
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